GeneOne Announces the Appointment of Kar Muthumani, M.S., Ph.D. as Chief Scientific Development Officer

Share Article

GeneOne Life Science, Inc., an international developer of DNA and RNA vaccines, nucleic acid-based therapeutics, and small molecule therapies, appoints Kar Muthumani, M.S., Ph.D. as Chief Scientific Development Officer.

GeneOne Logo
We are pleased that Dr. Muthumani is joining the GeneOne team. His 22 years of research involving vaccines and immunotherapies will complement GeneOne’s expanding footprint in the field of DNA and RNA vaccines and therapeutics.

GeneOne Life Science, Inc. (http://www.genels.com), announces the appointment of Kar Muthumani, M.S., Ph.D. as Chief Scientific Development Officer. The addition of Dr. Muthumani enhances GeneOne’s existing capabilities in the fields of DNA and RNA vaccines against Emerging Infectious Diseases, immunology, and oncology. During his time at the School of Medicine, University of Pennsylvania and more recently at the Wistar Institute, Dr. Muthumani developed ground-breaking vaccines against lethal and significant diseases such as HIV, CHIKV, MERS Coronavirus, Zika virus, Mayaro MAYV, Powassan (POWV) and the SARS-CoV-2 (COVID-19) coronavirus. His lab also developed a number of novel synthetic DNA-encoded monoclonal antibodies for infectious disease and cancer immunotherapies.

Young K. Park, President and Chief Executive Officer, said “We are pleased that Dr. Muthumani is joining the GeneOne team. His 22 years of research involving vaccines and immunotherapies will complement GeneOne’s expanding footprint in the field of DNA and RNA vaccines and therapeutics.”

Dr. Muthumani stated, “I am pleased to be joining GeneOne Life Science, Inc, a company that has demonstrated rapid advancement in gene-based immune therapies. Their seminal work in emerging infectious diseases and their highly integrated model of product development from concept to bedside, I would consider as best in the industry. I look forward to working with GeneOne on their novel and exciting nucleic acid and small molecule development programs for COVID-19 and other important disease targets with unmet medical needs.”

GeneOne Life Science, Inc. operates as a biopharmaceutical company in the United States and South Korea. The company researches and develops gene-based biomedicines, nucleic acid vaccines, and other immune related products.

ABOUT GENEONE LIFE SCIENCE
GeneOne Life Science, Inc. (“GeneOne” KOSPI: 011000) is an international developer of DNA and RNA vaccines, nucleic acid-based therapeutics, and small molecule therapies. GeneOne sponsored the MERS-001 and MERS-002 clinical trials against MERS-CoV and the ZIKA-001 and ZIKA-002 vaccine studies against the Zika virus. GeneOne’s research group has developed DNA vaccines and products to prevent and treat incurable diseases as well as hematologic diseases, metabolic diseases, and cancers. GeneOne is a recognized leader in the fight against Emerging Infectious Diseases (EIDs) with a pipeline to address a number of pathogenic organisms and participates in numerous international advisory committees regarding vaccine development against EIDs. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne's wholly-owned manufacturing subsidiary, located in Texas, is the leading cGMP DNA plasmid manufacturing facility in the world for the vaccine, cell therapy, and gene therapy industries. VGXI has manufactured numerous DNA vaccines against EIDs including the GLS-5300 against MERS-CoV and the first COVID-19 DNA vaccine into human clinical trials. For more information, visit http://www.genels.com and http://www.vgxii.com.

CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Grace (Eun Hae) Oh
Visit website